CO2022005113A2 - Métodos de tratamiento para modificar la hemodinámica - Google Patents
Métodos de tratamiento para modificar la hemodinámicaInfo
- Publication number
- CO2022005113A2 CO2022005113A2 CONC2022/0005113A CO2022005113A CO2022005113A2 CO 2022005113 A2 CO2022005113 A2 CO 2022005113A2 CO 2022005113 A CO2022005113 A CO 2022005113A CO 2022005113 A2 CO2022005113 A2 CO 2022005113A2
- Authority
- CO
- Colombia
- Prior art keywords
- human subject
- hemodynamics
- modify
- treatment methods
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
La invención proporciona un método de tratamiento que comprende la administración de un péptido AQGV, o un análogo funcional del mismo, a un sujeto humano, donde el sujeto humano opcionalmente tiene una función renal deteriorada, en donde el tratamiento para administrar un péptido AQGV comprende mantener o mejorar la estabilidad hemodinámica en el sujeto humano, como un sujeto humano que padece o se considera que padece la enfermedad de Clarkson (CLS).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962908442P | 2019-09-30 | 2019-09-30 | |
| US202063045752P | 2020-06-29 | 2020-06-29 | |
| PCT/NL2020/050605 WO2021066649A1 (en) | 2019-09-30 | 2020-09-30 | Methods of treatment for modifying hemodynamics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022005113A2 true CO2022005113A2 (es) | 2022-06-21 |
Family
ID=72811922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0005113A CO2022005113A2 (es) | 2019-09-30 | 2022-04-25 | Métodos de tratamiento para modificar la hemodinámica |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220370543A1 (es) |
| EP (1) | EP4037701A1 (es) |
| JP (1) | JP2023503790A (es) |
| KR (1) | KR20220106114A (es) |
| AU (1) | AU2020360113A1 (es) |
| CA (1) | CA3152346A1 (es) |
| CL (1) | CL2022000786A1 (es) |
| CO (1) | CO2022005113A2 (es) |
| MX (1) | MX2022003820A (es) |
| WO (1) | WO2021066649A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023521744A (ja) * | 2020-04-06 | 2023-05-25 | バイオテンプト ビー．ブイ． | 感染症における血行動態を変更する為の方法及び手段 |
| CA3197477A1 (en) * | 2020-09-30 | 2022-04-07 | Biotempt B.V. | Autophagy-inhibiting peptide and organic acid salt thereof addressing issues of vascular permeability |
| WO2023059188A1 (en) * | 2021-10-05 | 2023-04-13 | Biotempt B.V. | Angiogenic control, preferably combined with glycaemic control. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1466612A1 (en) * | 2003-04-08 | 2004-10-13 | Biotempt B.V. | Treatment of inflammation and sepsis with hCG derived peptides |
| DK2120991T3 (da) * | 2007-02-12 | 2014-04-28 | Biotempt Bv | Behandling af traumatisk blødning med korte oligopeptider |
| WO2009014440A1 (en) * | 2007-07-23 | 2009-01-29 | Biotempt B.V. | Inhibition of renal ischemia reperfusion injury by synthetic oligopeptides |
-
2020
- 2020-09-30 EP EP20789291.0A patent/EP4037701A1/en active Pending
- 2020-09-30 AU AU2020360113A patent/AU2020360113A1/en active Pending
- 2020-09-30 US US17/765,162 patent/US20220370543A1/en active Pending
- 2020-09-30 JP JP2022520329A patent/JP2023503790A/ja active Pending
- 2020-09-30 KR KR1020227013941A patent/KR20220106114A/ko unknown
- 2020-09-30 CA CA3152346A patent/CA3152346A1/en active Pending
- 2020-09-30 MX MX2022003820A patent/MX2022003820A/es unknown
- 2020-09-30 WO PCT/NL2020/050605 patent/WO2021066649A1/en unknown
-
2022
- 2022-03-29 CL CL2022000786A patent/CL2022000786A1/es unknown
- 2022-04-25 CO CONC2022/0005113A patent/CO2022005113A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023503790A (ja) | 2023-02-01 |
| CL2022000786A1 (es) | 2022-11-04 |
| CA3152346A1 (en) | 2021-04-08 |
| AU2020360113A1 (en) | 2022-04-14 |
| WO2021066649A1 (en) | 2021-04-08 |
| KR20220106114A (ko) | 2022-07-28 |
| MX2022003820A (es) | 2022-09-19 |
| EP4037701A1 (en) | 2022-08-10 |
| US20220370543A1 (en) | 2022-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022005113A2 (es) | Métodos de tratamiento para modificar la hemodinámica | |
| CY1122428T1 (el) | Θεραπευτικη αγωγη της παιδιατρικης οξειας λεμφοβλαστικης λευχαιμιας με διειδικα αντισωματα εναντι cd3xcd19 | |
| CL2018001677A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| GT201400166A (es) | Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardiaca | |
| MD3532486T2 (ro) | Compuși de tirozină-tirozină peptidică ciclică cuplaţi la anticorp ca modulatori de receptori Y ai neuropeptidei | |
| CO6341486A2 (es) | Tratamiento y profilaxis de amiloidosis | |
| CL2020000491A1 (es) | Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabry. | |
| AR115583A1 (es) | Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado | |
| AR111374A1 (es) | Uso de lik066 en pacientes con insuficiencia cardíaca | |
| EA202191175A1 (ru) | Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры | |
| CO2022004902A2 (es) | Anticuerpo anti beta-amiloide para el tratamiento de la enfermedad de alzheimer | |
| EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
| MX2019009586A (es) | Composiciones y metodos para tratar enfermedades asociadas con la permeabilidad del epitelio intestinal. | |
| MX2020002802A (es) | Anticuerpos de cadena pesada que se unen a ectoenzimas. | |
| MX2021011269A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina. | |
| BR112018068960A2 (pt) | formulações de enalapril | |
| EA202190057A1 (ru) | Солюбилизированные апиразы, способы и применение | |
| DOP2021000215A (es) | Tratamiento de la cefalea usando anticuerpo anti-cgrp | |
| AR117861A1 (es) | Métodos de reducción de eventos cerebrovasculares en pacientes con enfermedad de fabry | |
| EA202191165A1 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
| EA202190226A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ | |
| EA202191058A1 (ru) | Антитела против муцина-16 и способы их применения | |
| BR112017004590A2 (pt) | métodos para o tratamento de doença autoimune com o uso de um anticorpo de domínio direcionado contra cd40l | |
| EA202090028A1 (ru) | Способы уменьшения или предотвращения сердечно-сосудистых явлений у пациентов с сахарным диабетом ii типа | |
| CL2022001177A1 (es) | Tregímenes de dosificación para usar en el tratamiento de la mielofibrosis y trastornos relacionados con nmp con navitoclax. |